Big Pharma Talks Deal-Making Risk At TAP
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaceutical executives discuss their frustration with risky novel therapeutics that biotechs are developing.
You may also be interested in...
FDA Issues Complete Response Letter for Arena's Lorcaserin
Concerrns Raised by Advisory Committee Come Back to Haunt Lorcaserin, the company's first product to go through regulatory process.
Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration
As in its Dimebon collaboration with Pfizer, the biotech gets significant U.S. profit-sharing along with an option for co-promotion.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.